The levels of serum sFas and sFasL in patients with acute cerebral infarction： an observational study

Abstract

Objective To investigate the changes of serum soluble Fas （sFas） and soluble Fas-ligand （sFasL）, and the relationship betweenthe level of serum sFas or sFasL and the infarct volume in patients with acute cerebral infarction （ACI）. Methods Sixty patients with ACI （female 28, male 32） served as study group and 30 healthy subjects （female 18, male 12） served as control group. An enzyme-linked immunosorbent assay was used to detect the levels of serum sFas and sFasL in both groups, and the differences of the sFas and sFasL concentration were compared between the two groups. Results The levels of serum sFas at 48 hours, at day 7 and 14 in the ACl group were 6. 27 ± 1.48 ng/L, 4. 99 ± 1.15 ng/L, and 3.74 ± 0.58 ng/L,respectively, and they were all significantly higher than 3.00 ± 0. 38 ng/L in the control group （P 〈0. 05）. The levels of serum sFasL at 48 hours, at day 7 and 14 in the ACI group were 4.40 ± 1.32 ng/L, 3. 19 ± 0.94 ng/L, and 1.91±0.45 ng/L, respectively. They were significantly higher than 1.15 ±0.21 ng/L in the control group （P〈0.01）. The levels of sFas （1.91 ± 0.45） ng/L, respectively, and they were all significantly higher than （4.98 ±0.91） ng/L（t = 12.12 ,P 〈0. 01）and （3.58 ±0. 87） ng/L（t =5.35 ,P 〈0.01） in the small infarction group. The levels of serum sFas and sFasL in patients with ACI showed positive correlation （r =0. 748, P =0. 01）. Conclusions High serum sFas and sFasL may indicate larger infarct volume in patients with ACI. Key words: Brain infarction; Antigens, CD95; Fas ligand protein; Apoptosis